Drug Discovery Outsourcing: World Market Forecast 2014-2024

Description

Drug Discovery Outsourcing: WorldDrug Discovery Outsourcing: World Market Forecast 2014-2024 PR Newswire LONDON, January 20, 2014 & Future Prospects for Leading Companies Drug discovery outsourcing - discover trends and segments with highest revenue potential What does the future hold for drug discovery outsourcing? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our new study is your guide to the potential of those pharmaceutical services. It lets you assess projected sales at world market, submarket and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions. In our investigation you also see qualitative analyses, new R&D and business developments. Our 194 page report provides 152 tables, charts, and graphs. Read the full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales: - Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience, Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium - Dr.

Informations

• Publié par: visiongain
• Publié le: 20 janvier 2014
• Nombre de lectures: 41
• Langue: English

Extrait

Drug Discovery Outsourcing: World Market Forecast 2014-2024

PR Newswire

LONDON, January 20, 2014

& Future Prospects for Leading Companies

Drug discovery outsourcing  - discover trends and segments with highest revenue potential

What does the future hold for drug discovery outsourcing? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our new study is your guide to the potential of those pharmaceutical services. It lets you assess projected sales at world market, submarket and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions.

In our investigation you also see qualitative analyses, new R&D and business developments. Our 194 page report provides 152 tables, charts, and graphs. Read the full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience, Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium
- Dr. Mark Craighead, Director of Scientific Strategy, Redx Pharma

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of four outsourcing submarkets at world level to 2024:
• Chemical services
• Biological services
• Lead optimisation
• Lead identification and screening

With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery.

To see an exec summary of this report please email Sara Peerun on [e-mail]

What are the prospects in leading regions and countries?

Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients.

In our study you will find individual revenue forecasts to 2024 for 12 national markets:
•    US
•    Japan
•    UK
•    Germany
•    France
•    Spain
•    Italy
•    China
•    India
•    Brazil
•    Russia
•    South Korea
•    RoW

Emerging economies have large, highly educated workforces and competitive price regimes. Therefore countries like China and India continue to rapidly emerge as important outsourcing destinations for research and manufacturing.
Greater uptake of existing technology worldwide will also stimulate the industry and market.

Leading companies and potential for market growth

Overall world revenue for that market area will reach $14.9bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what services and organisations hold greatest potential. See profiles of 13 leading companies, including these:
•    Albany Molecular Research (AMRI)
•    Aptuit
•    Charles River Laboratories
•    Covance
•    Cyprotex
•    Domainex
•    Evotec
•    Galapagos
•    GenScript
•    Pharmaceutical Product Development (PPD)
•    Quintiles
•    WIL Research Laboratories
•    WuXi AppTec

In general, a company profile gives you the following information
•    Discussion of a company's activities and outlook
•    Recent financial results
•    Assessment of recent developments - mergers and acquisitions (M&A) and collaborations.
•    Drug discovery revenue forecasts to 2024

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

To see an exec summary of this report please email Sara Peerun on [e-mail]

What issues will affect outsourced drug discovery?

Our new report discusses issues and events affecting early-stage drug development. You will find discussions, including qualitative analyses:
•    Increasing focus on biologic drugs continues to provide CROs with expansion opportunities
•    Changing R&D models in the pharmaceutical industry
•    Progress in target identification, validation, chemistry, biology and ADMET screening
•    Emerging markets offering reprieve from the effects of cost pressures and declining R&D budgets

Also, you find coverage of these aspects:
•    Regional expansion, competition and CRO consolidation
•    Niche CROs and virtual pharmaceutical companies
•    Technology transfer and intellectual property (IP)
•    Competition from private-public partnerships

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies  report helps you

In summary, our 194 page report gives you the following knowledge:
•    Revenues forecasts to 2024 for the overall world drug discovery outsourcing market and 4 submarkets - discover the industry's prospects, finding promising places for investments and revenues
•    Assessment of 13 leading companies, and others, discovering activities and outlooks
•    Market forecasting to 2024 for 12 national markets - US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China, South Korea and RoW.
•    View opinions from our survey, seeing interviews with authorities
•    Investigation of competition and opportunities influencing sales
•    Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for outsourced drug discovery. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            [e-mail] or call Tel : [phone]

Or click on http://www.visiongain.com/Report/1180/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024

Companies Listed

Abbott
Accugenix
Advion Bioanalytical
Albany Molecular Research Inc (AMRI)
Andromeda Biotech (Teva)
Apredica (Cyprotex)
Aptuit
Argenta (Galapagos)
AstraZeneca
Bayer
Behrman Capital
BioCity
BioDuro (PPD)
BioFocus (Galapagos)
Biopontis Alliance
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Carlyle Group
Catalent Pharma Solutions
Cerebricon (Charles River)
Charles River Laboratories
ChemBridge
ChemDiv
Compound Focus (Evotec)
Covance
Crucell
Cyprotex
Discovery Partners International
Domainex
Dow AgroSciences
Dow Chemical Company
Elan
Eli Lilly
Evotec
Fidelity Growth Partners India (FGPI)
Fidelta (Galapagos)
Furiex Pharmaceuticals
Galapagos
Genentech
GenScript
GlaxoSmithKline (GSK)
Glycoform
Great Lakes Chemical Corporation
Hangzhou Tigermed Consulting
Hellman & Friedman
Hypha Discovery
i3 Research (inVentiv Health)
ICON
Inpharmatica
InSphero
InVentiv Health
Johnson & Johnson (J&J)
Janssen Pharmaceutical Group
Kinaxo
Knopp Biosciences
ICON
Immatics
JOINN Laboratories
Laurus Labs
Lonza
MAB Discovery
MedImmune
Merck & Co.
Microsoft
Midwest BioResearch (WIL Research)
Millipore
Novartis
Ono Pharmaceutical
Oxford Asymmetry International
Parexel
Peking Union Lawke Biomedical Development Limited (PUL)
Pfizer
Myriad RBM
Pharmaceutical Product Development (PPD)
Pharmidex
PharmaNet Development Group (inVentiv Health)
Pharminox
Piedmont Research Center (Charles River)
PRA International
ProSkelia
ProStrakan
Proteome Sciences
Proteros Biostructures GmbH (Proteros)
ProtonMedia
Quintiles
Ricerca Biosciences (WIL Research)
Roche
Samsung
Sanofi
Sareum Holdings Plc
Servier
ShangPharma Corporation
Shionogi
Sirius Analytical
Solvo Biotechnology
Swiss Pharma Contract
Sygnature Discovery
SYNthesis Med Chem
Taijitu Biologics
Takeda
Teva
The Dow Chemical Company
Tibotec
TRAC Microbiology
TransGenic
UCB
VitualScopics
WIL Research Laboratories
WuXi AppTec
WuXi PharmaTech

Other Organisations Mentioned in This Report